Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clarus Corporation - Common Stock (NQ:CLAR)

3.530 -0.040 (-1.12%)
Streaming Delayed Price Updated: 11:03 AM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Clarus Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
Trump's Tariff Storm: 3 Survival Strategies US Companies Are Using To Fight Back
US companies prepare for potential tariff increases under Trump administration. Strategies include passing costs to customers, stockpiling imports, and shifting supply chains. 
Via Benzinga
Topics Government World Trade
Clarus (NASDAQ:CLAR) Misses Q3 Revenue Estimates
Outdoor lifestyle and equipment company Clarus (NASDAQ:CLAR) fell short of the market’s revenue expectations in Q3 CY2024, with sales falling 17.4% year on year to $67.12 million. The company’s... 
Via StockStory
What To Expect From Clarus’s (CLAR) Q3 Earnings
Outdoor lifestyle and equipment company Clarus (NASDAQ:CLAR) will be reporting earnings tomorrow after market hours. Here’s what to expect. 
Via StockStory
12 Consumer Discretionary Stocks Moving In Friday's Intraday Session
Via Benzinga
CLAR Stock Earnings: Clarus Beats Revenue for Q1 2024
CLAR stock results show that Clarus beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Thursday Is Your Last Chance To Buy Clarus Before The Dividend Payout
Via Benzinga
Clarus: Q4 Earnings Insights
Via Benzinga
12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Consumer Discretionary Stocks Moving In Friday's Intraday Session
Via Benzinga
CLAR Stock Earnings: Clarus Misses EPS, Misses Revenue for Q4 2023
CLAR stock results show that Clarus missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Few Aspects Of Clarus' Sales Of Precision Sport Segment Seems Odd, Says Analyst
Raymond James analyst Joseph Altobello reiterated a Market Perform rating on the shares of Clarus Corp (NASDAQ: CLAR).  
Via Benzinga
12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Friday Is Your Last Chance To Buy Clarus Before The Dividend Payout
Via Benzinga
Clarus: Q3 Earnings Insights
Via Benzinga
Analyst Ratings for Clarus
Via Benzinga
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Clarus's Ex-Dividend Date Is Friday, Here's What You Need To Know
Via Benzinga
12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Fostering Confidence: Clarus Reliable Progress and Investor Expectations
Today, August 25, 2023, marks an important moment for investors of Clarus (NASDAQ:CLAR). The company will distribute a dividend payout of $0.03 per share, demonstrating an annualized dividend yield of... 
Via Benzinga
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
Earnings Preview: Clarus
Via Benzinga
Expert Ratings for Clarus
Via Benzinga
12 Consumer Discretionary Stocks Moving In Monday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Via Benzinga
What 4 Analyst Ratings Have To Say About Clarus
Via Benzinga
Clarus: Dividend Insights
Via Benzinga
Clarus Earnings Preview
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
10 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For May 1, 2023
Companies Reporting Before The Bell • TG Therapeutics (NASDAQ:TGTX) is estimated to report quarterly loss at $0.37 per share on revenue of $3.38 million. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.